ChromaDex (CDXC) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ChromaDex Corporation Reports 2020 Financial Results
March 10, 2021 4:02 PM ESTRevenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses. Full Year Revenue of $59.3 Million, with $47.1 Million from Tru Niagen®.
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) today reported fourth quarter and full year 2020 financial results.
Fourth Quarter 2020 and Recent Highlights
Total net sales of $15.4 million, up 18% from $13.1 million in the year ago quarter. Tru Niagen® net sales of $12.3 million, a 21% increase from the year ago quarter. Gross margin... More